PONIARD PHARM (NASDAQ:PARD)

2.53

+0.16 (6.75%)

PONIARD PHARM (NASDAQ:PARD) Delayed :
Previous Close	$2.37	52 Week High	$9.14
Open	$2.30	52 Week Low	$1.05
Day High	$2.54	P/E	N/A
Day Low	$2.21	EPS	$-1.35
Volume	8,338,000
More PARD Info: Chart SEC Filings Profile Historical Options

What is this?Friends, Peers and Foes

Ticker	# Stories	Ticker	# Stories
ALTH	3	PSUN	3
EXEL	3	GSK	3
ALKS	3	CRXX	3
NABI	3	SNY	3
SPEX	3	UAUA	3
XJT	3	ZOOM	2

View All Entities

Nov 16, 2009 07:16 AM Poniard Pharma (PARD) SPEAR Phase III of Picoplatin Did Not Meet Survival Endpoint
Nov 3, 2009 05:30 PM Poniard Pharma (PARD) Posts Q3 Loss of $0.29, In-Line with Estimates
Aug 4, 2009 04:24 PM Poniard Pharma (PARD) Reports Q2 Loss of $0.28, Beats by 6c

Nov 18, 2009 10:55 AM Notable Analyst Rating Changes 11/18: SII, ZMH, FSLR, PHM Upgraded; TGT, ADSK, VIP, JEC, PARD Downgraded
Nov 18, 2009 10:16 AM Morning Movers 11/18: ABK, CHS, LDK, RDN Higher; ONCY, NANO, EXEL, ADSK, CNQR Lower
Nov 18, 2009 09:12 AM Canaccord Adams downgrades Poniard Pharmaceuticals (PARD) to Hold; Less Attractive Risk/Reward
Nov 18, 2009 08:26 AM Canaccord Adams Downgrades Poniard Pharmaceuticals (PARD) to Hold
Nov 17, 2009 02:02 PM Unusual 11 Mid-Day Movers 11/17: SMTL, PARD, AGO, ZOOM, HEAT Higher; KFS, INOC, FTK, TBUS Lower

Nov 17, 2009 12:52PM Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
Nov 17, 2009 06:50AM Trading Overview for Poniard Pharmaceuticals Inc. Issued by Beacon Equity
Nov 16, 2009 07:00AM Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer Did Not Meet Primary Endpoint
Nov 15, 2009 07:10PM Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
Nov 13, 2009 08:02PM Semi-Annual Changes to the NASDAQ Biotechnology Index

Nov 18, 2009 12:58 PM Poniard Pharmaceuticals' Gamble Doesn't Pay Off
Nov 18, 2009 11:45 AM Analyst upgrades, downgrades and initiations: FIS, LMNX, RIMM, SII, TGT, TSYS ...
Nov 17, 2009 04:01 PM Tuesday Options Recap
Nov 17, 2009 05:02 AM BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
Nov 16, 2009 04:16 PM Monday Options Recap

Nov 20, 2009 03:40PM Form 8-K PONIARD PHARMACEUTICALS, For: Nov 17
Nov 18, 2009 01:44PM Form SC 13D/A PONIARD PHARMACEUTICALS, Filed by: MPM BIOVENTURES III LP
Nov 17, 2009 07:01PM Form 4 PONIARD PHARMACEUTICALS, For: Nov 15 Filed by: JACKSON MICHAEL K
Nov 16, 2009 07:30AM Form 8-K PONIARD PHARMACEUTICALS, For: Nov 16
Nov 9, 2009 06:59PM Form 4 STEINMETZ MICHAEL For: Nov 05

Bob Weidman
on Nov 16, 2009
at 01:24 PM Insider Trading! Luke Evnin, listed as a 10% or greater owner, sold all of his stock on November 5. Gee, you think he had inside information?
Article: Needham & Co Downgrades Poniard Pharmaceuticals (PARD) to Hold on Phase 3 SPEAR Trial Results
ANDREW OLIVER SATCHELL
on Nov 13, 2009
at 03:55 PM ANDREW OLIVER SATCHELL EXCELLENT
Article: Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report

No comments are currently available.